Please wait while the formulary information is being retrieved.
MELPHALAN (MELPHALAN)
- Malignant neoplasm of the ovary
- Multiple myeloma
2 mg tablet
- 1 tablet (2 mg) by oral route once daily
2 mg tablet
- 1 tablet (2 mg) by oral route once daily
Malignant neoplasm of the ovary
- 0.2 mg/kg by oral route once daily for 5 days
Multiple myeloma
- 0.2 mg/kg by oral route once daily for 5 days
- 0.25 mg/kg by oral route once daily for 4 days
- 1 tablet (2 mg) by oral route once daily
- zoster vaccine live (PF)
- Zostavax (pf)
- Yf-vax (pf)
- yellow fever vaccine live (PF)
- Vivotif Berna Vaccine
- Varivax (pf)
- varicella virus vacc live (PF)
- Tysabri
- typhoid vaccine
- rotavirus vaccine live, penta
- Rotateq Vaccine
- Proquad (pf)
- natalizumab
- measles,mumps,rub,varicel(PF)
- measles,mumps&rubella vacc(PF)
- M-m-r Ii (pf)
- Flumist 2013-2014
- flu vac,qval 2013-14 (2-49yrs)
- BCG vaccine, live (PF)
- adenovirus vaccine live type-7
- adenovirus vaccine live type-4
- adenovirus vac live type-4 & 7
Contraindicated
- Versacloz
- Ferriprox
- Fazaclo
- deferiprone
- Clozaril
- clozapine
Severe
Moderate
- None
- Drug-induced hepatitis
- Hemolytic anemia
- Hepatic veno-occlusive disease
- Interstitial pneumonitis
- Lactating mother
- Pulmonary fibrosis
- Severe infection
Contraindicated
- Anemia
- Bone marrow depression
- Granulocytopenic disorder
- Hemorrhage
- Kidney disease with reduction in GFR
- Leukopenia
- Pregnancy
- Thrombocytopenic disorder
- Vasculitis
Severe
Moderate
- Abnormal hepatic function tests
MELPHALAN (MELPHALAN)
- Malignant neoplasm of the ovary
- Multiple myeloma
- Anemia
- Bone marrow depression
- Infection
- Leukopenia
- Neutropenic disorder
- Thrombocytopenic disorder
- None
More Frequent
Severe
Less Severe
- Allergic dermatitis
- Anaphylaxis
- Pruritus of skin
- Skin rash
- Alopecia
- Diarrhea
- Nausea
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Acute myeloid leukemia
- Dermal necrosis
- Extravasation injury
- Hepatic veno-occlusive disease
- Hepatitis
- Hyperuricemia
- Interstitial pneumonitis
- Obstructive hyperbilirubinemia
- Pulmonary fibrosis
- Stomatitis
- Urticaria
- Vasculitis
Less Severe
- Amenorrhea
- Sensation of warmth
Contraindicated
None
Severe Precaution
Melphalan
Risk of severe bone marrow depression. No established safety and efficacy.
- 1 Day – 13 Years
- Risk of severe bone marrow depression. No established safety and efficacy.
Management or Monitoring Precaution
None
Melphalan
- Severity Level:
D
- Additional Notes: Based on drug pharmacology dev tox may occur; animal data sug dev tox
Contraindicated
Melphalan
Not recommended, risk of severe toxicity.
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Not recommended, risk of severe toxicity. |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Although melphalan is used to treat cancer, it may rarely increase your risk of developing other cancers. Also, melphalan may cause a severe decrease in your blood cells, which lowers your ability to fight infections and increases the risk of anemia/bleeding problems. You may be more likely to get a serious (rarely fatal) infection or any infection you have may get worse.<br /><br /> Tell your doctor right away if you develop unusual growths or lumps, swollen glands, signs of infection (such as a sore throat that doesn't go away, fever, chills), easy or unusual bruising/bleeding, or unusual tiredness. Taking melphalan during pregnancy may increase the risk of birth defects. Also, it may make it harder for men or women to have a child (decreased fertility) after treatment. Talk with your doctor about the risks and benefits of treatment with this medication.
| Malignant neoplasm of the ovary | |
| C56 | Malignant neoplasm of ovary |
| C56.1 | Malignant neoplasm of right ovary |
| C56.2 | Malignant neoplasm of left ovary |
| C56.9 | Malignant neoplasm of unspecified ovary |
| Multiple myeloma | |
| C90.0 | Multiple myeloma |
| C90.00 | Multiple myeloma not having achieved remission |
| C90.02 | Multiple myeloma in relapse |
| 0-9 | A-Z |
|---|---|
| C56 | Malignant neoplasm of ovary |
| C56.1 | Malignant neoplasm of right ovary |
| C56.2 | Malignant neoplasm of left ovary |
| C56.9 | Malignant neoplasm of unspecified ovary |
| C90.0 | Multiple myeloma |
| C90.00 | Multiple myeloma not having achieved remission |
| C90.02 | Multiple myeloma in relapse |
Formulary Reference Tool